- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02170909
Safety, Pharmacokinetics and Pharmacodynamics of BIBR 1048 MS Capsule in Healthy Male Subjects of Japanese and Caucasian Origin
29 augustus 2018 bijgewerkt door: Boehringer Ingelheim
Safety, Pharmacokinetics and Pharmacodynamics After Single (150 mg, 220 mg and 300 mg) and Multiple (150 mg and 220 mg q.d. and 150 mg b.i.d.) Rising Oral Doses of BIBR 1048 MS/Capsules in Healthy Male Subjects of Japanese and Caucasian Origin. (Open Label Study)
Study to investigate and compare safety, pharmacokinetics and pharmacodynamics of BIBR 1048 MS following oral administration of single (150 mg, 220 mg and 300 mg) and multiple (150 mg and 220 mg q.d. and 150 mg b.i.d.) rising doses in healthy male subjects of Japanese and Caucasian origin.
Studie Overzicht
Toestand
Voltooid
Conditie
Interventie / Behandeling
Studietype
Ingrijpend
Inschrijving (Werkelijk)
42
Fase
- Fase 1
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
20 jaar tot 45 jaar (Volwassen)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Mannelijk
Beschrijving
Inclusion Criteria:
Healthy male subjects of Japanese or Caucasian origin according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate, respiratory rate and tympanic body temperature), 12- lead ECG (electrocardiogram), clinical laboratory tests
- 1.1 No finding deviating from normal and of clinical relevance
- 1.2 No evidence of a clinically relevant concomitant disease
- Age ≥ 20 and Age ≤ 45 years
- Body mass index (BMI) ≥ 18 and ≤ 25 kg/m2
- Japanese subjects were from a well-defined Japanese population, both parents of Japanese origin and the subjects have Japanese passport and had lived ≤ 8 years outside Japan.
- Signed and dated written informed consent prior to admission to the study in accordance with GCP (Good Clinical Practice) and the local legislation.
Exclusion Criteria:
- Current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- An unwillingness of male subjects to abstain from sexual intercourse with pregnant or lactating women, or an unwillingness of male subjects to use an adequate form of contraception as well as having their female partner(s) use another form of contraception (if the woman possibly become pregnant) from the time of the single dose on Day 1 until Day 22-26 (end-of study examination)
- Current diseases of the central nervous system (such as epilepsy), or psychiatric disorders or neurological disorders
- History of clinically significant orthostatic hypotension, clinically significant current or past fainting spells or blackouts
- Chronic or relevant acute infections
History of
- allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- any bleeding disorder including prolonged or habitual bleeding
- other hematologic disease
- cerebral bleeding (e.g. after a car accident)
- concussions (head trauma resulting in injuring to brain) with or without loss of consciousness
- Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives, whichever is shorter, of the respective drug prior to administration or during the trial
- Use of acetylsalicylic acid (ASA)-containing over-the-counter medications, clopidogrel or ticlopidine or dipyridamole, chronic administration of non-steroidal anti-inflammatory drugs (NSAIDs) (cyclooxygenase-2 (COX-2) inhibitors excluded), coumadin like anticoagulants, chronic use of corticosteroids, heparin and fibrinolytic agents within 14 days prior to administration or during the trial.
- Participation in another trial with an investigational drug within three months prior to administration or during the trial
- Smoker (> 10 cigarettes/day or > 3 cigars/day or > 3 pipes/day)
- Inability to refrain from smoking on trial days
- Alcohol abuse (more than 21unit/week; one unit was approximately half a pint of beer, a small glass of wine or one measure of spirits)
- History of drug abuse
- Blood donation (more than 100 mL within three months prior to screening administration and any blood donation from screening to end-of-study examination)
- Excessive physical activities (within one week prior to administration or during the trial and until end-of-study examination)
- Any laboratory value outside the reference range that was of clinical relevance
- Inability to comply with dietary regimen of study centre
- Known hypersensitivity to the drug or its excipients
- History of any familial bleeding disorder
- Thrombocytes < 150000/μL
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: BIBR 1048 MS low dose
|
|
Experimenteel: BIBR 1048 MS medium dose
|
|
Experimenteel: BIBR 1048 MS high dose
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Change in vital signs
Tijdsspanne: Baseline and up to day 26
|
Baseline and up to day 26
|
Change in 12-lead electrocardiogram (ECG)
Tijdsspanne: Baseline and up to day 26
|
Baseline and up to day 26
|
Change in clinical laboratory tests
Tijdsspanne: Baseline and up to day 26
|
Baseline and up to day 26
|
Occurence of adverse events
Tijdsspanne: Up to day 26
|
Up to day 26
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Area under the curve (AUC) from 0-24 hours for activated partial thromboplastin time (aPTT)
Tijdsspanne: Day 1 and 12
|
Day 1 and 12
|
AUC from 0-24 hours for ecarin clotting time (ECT)
Tijdsspanne: Day 1 and 12
|
Day 1 and 12
|
Change in thrombin time (TT)
Tijdsspanne: Baseline and up to 72 hours after administration on day 1 and 12
|
Baseline and up to 72 hours after administration on day 1 and 12
|
Change in prothrombin time (PT) expressed as international normalised ratio (INR)
Tijdsspanne: Baseline and up to 72 hours after administration on day 1 and 12
|
Baseline and up to 72 hours after administration on day 1 and 12
|
Maximum value of aPTT
Tijdsspanne: Up to 72 hours after administration on day 1 and 12
|
Up to 72 hours after administration on day 1 and 12
|
Maximum value of ECT
Tijdsspanne: Up to 72 hours after administration on day 1 and 12
|
Up to 72 hours after administration on day 1 and 12
|
Change in ECT
Tijdsspanne: Baseline and up to 72 hours after administration on day 1 and 12
|
Baseline and up to 72 hours after administration on day 1 and 12
|
Change in aPTT
Tijdsspanne: Baseline and up to 72 hours after administration on day 1 and 12
|
Baseline and up to 72 hours after administration on day 1 and 12
|
Cmax (maximum measured concentration of the analyte in plasma)
Tijdsspanne: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
tmax (time from dosing to maximum measured concentration of the analyte in plasma)
Tijdsspanne: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
AUCτ,1 (area under the concentration-time curve of the analyte in plasma over a uniform dosing interval τ after administration of the single dose on day 1)
Tijdsspanne: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable drug plasma concentration)
Tijdsspanne: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)
Tijdsspanne: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
λz (terminal rate constant in plasma)
Tijdsspanne: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
t1/2 (terminal half-life of the analyte in plasma)
Tijdsspanne: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
MRTpo (mean residence time of the analyte in the body after po administration)
Tijdsspanne: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
CL/F (apparent clearance of the analyte in plasma following extravascular administration)
Tijdsspanne: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular administration)
Tijdsspanne: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
Aet1-t2 (amount of analyte that is eliminated in urine from the time point t1 to time point t2)
Tijdsspanne: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
fet1-t2 (fraction of analyte eliminated in urine from time point t1 to time point t2)
Tijdsspanne: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2)
Tijdsspanne: Up to 72 hours after administration on day 1
|
Up to 72 hours after administration on day 1
|
Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ)
Tijdsspanne: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state)
Tijdsspanne: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
Cmin,ss (minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ)
Tijdsspanne: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)
Tijdsspanne: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
λz,ss (terminal rate constant in plasma at steady state)
Tijdsspanne: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
t1/2,ss (terminal half-life of the analyte in plasma at steady state)
Tijdsspanne: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
MRTpo,ss (mean residence time of the analyte in the body at steady state after po administration)
Tijdsspanne: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
CL/F,ss (apparent clearance of the analyte in the plasma at steady state after extravascular multiple dose administration)
Tijdsspanne: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration)
Tijdsspanne: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
Aet1-t2,ss (amount of analyte that is eliminated in urine at steady state from the time point t1 to time point t2)
Tijdsspanne: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
fet1-t2,ss (fraction of analyte eliminated in urine at steady state from time point t1 to time point t2)
Tijdsspanne: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
CLR,t1-t2,ss (renal clearance of the analyte in plasma from the time point t1 until the time point t2 at steady state)
Tijdsspanne: Up to 72 hours after the last dose on day 12
|
Up to 72 hours after the last dose on day 12
|
Accumulation ratio RA,Cmax,7 based on Cmax
Tijdsspanne: Day 6 to day 15
|
Day 6 to day 15
|
Accumulation ratio RA,AUC,7 based on AUCτ (only for 150 mg and 220 mg q.d. groups)
Tijdsspanne: Day 6 to day 15
|
Day 6 to day 15
|
Linearity index (LI) based on AUC (only for 150 mg and 220 mg q.d. groups)
Tijdsspanne: Day 6 to day 15
|
Day 6 to day 15
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Nuttige links
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start
1 december 2004
Primaire voltooiing (Werkelijk)
1 juni 2005
Studieregistratiedata
Eerst ingediend
20 juni 2014
Eerst ingediend dat voldeed aan de QC-criteria
20 juni 2014
Eerst geplaatst (Schatting)
23 juni 2014
Updates van studierecords
Laatste update geplaatst (Werkelijk)
31 augustus 2018
Laatste update ingediend die voldeed aan QC-criteria
29 augustus 2018
Laatst geverifieerd
1 augustus 2018
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 1160.29
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Gezond
-
University of LeicesterNational Institute for Health Research, United KingdomVoltooidPatiënten met hartfalen en behouden ejectiefractie - HFpEF | Patiënten met hartfalen met verminderde ejectiefractie - HFrEF | Healthy Controls Group - Leeftijd en geslacht afgestemd
-
University Hospital, GrenobleUniversity Hospital, Clermont-Ferrand; Grenoble Institut des NeurosciencesBeëindigdZiekte van Parkinson | Healthy Controls Group - Leeftijd en geslacht afgestemdFrankrijk
Klinische onderzoeken op BIBR 1048 MS low dose
-
Boehringer IngelheimVoltooid
-
Boehringer IngelheimVoltooid
-
Boehringer IngelheimVoltooid
-
Boehringer IngelheimVoltooid
-
Boehringer IngelheimVoltooid
-
Boehringer IngelheimVoltooid
-
Boehringer IngelheimVoltooid
-
Boehringer IngelheimVoltooid